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Background: Early reperfusion of the occluded coronary artery during acute myocardial infarction is considered
crucial for reduction of infarcted mass and recovery of ventricular function. Effective microcirculation and the
balance between protective and harmful lymphocytes may have roles in reperfusion injury and may affect final
ventricular remodeling.
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Methods/design: BATTLE-AMI is an open-label, randomized trial comparing the effects of four therapeutic strategies
(rosuvastatin/ticagrelor, rosuvastatin/clopidogrel, simvastatin plus ezetimibe/ticagrelor, or simvastatin plus ezetimibe/
clopidogrel) on infarcted mass and left ventricular ejection fraction (LVEF) (blinded endpoints) in patients with ST-segment
elevation myocardial infarction submitted to fibrinolytic therapy before coronary angiogram (pharmacoinvasive strategy).
All patients (n = 300, 75 per arm) will be followed up for six months. The effects of treatment on subsets of B and T
lymphocytes will be determined by flow-cytometry/ELISPOT and will be correlated with the infarcted mass, LVEF, and
microcirculation perfusion obtained by cardiac magnetic resonance imaging. The primary hypothesis is that the
combined rosuvastatin/ticagrelor therapy will be superior to other therapies (particularly for the comparison with
simvastatin plus ezetimibe/clopidogrel) for the achievement of better LVEF at 30 days (primary endpoint) and
smaller infarcted mass (secondary endpoint) at 30 days and six months. The trial will also evaluate the improvement in
the immune/inflammatory responses mediated by B and T lymphocytes. Omics field (metabolomics and proteomics)
will help to understand these responses by molecular events.
Discussion: BATTLE-AMI is aimed to (1) evaluate the role of subsets of lymphocytes on microcirculation improvement
and (2) show how the choice of statin/antiplatelet therapy may affect cardiac remodeling after acute myocardial
infarction with ST elevation.
Trial registration: ClinicalTrials.gov, NCT02428374. Registered on 28 September 2014.
Keywords: Acute myocardial infarction, B lymphocytes, cardiac magnetic resonance imaging, metabolomics,
proteomicsBackground
An early invasive strategy after fibrinolysis has been
proven safe and effective among patients with
ST-segment elevation myocardial infarction (STEMI) [1,
2]. However, during acute myocardial infarction (MI),
some ligands of the injured tissue are recognized by the
innate immune system, triggering the mobilization of in-
flammatory cells. Yet experimental studies reported that
subsets of B lymphocytes may affect the healing process
of injured tissue due to the mobilization of monocytes,
subsequently affecting ventricular remodeling [3–6]. An
increased number of circulating platelets and monocyte
microparticles also seems to be related to the severity of
the acute MI [7]. Furthermore, it is possible that subsets
of lymphocytes and derived microparticles from B or T
cells contribute additionally to myocardial injury after
reperfusion, due to the release of highly inflammatory
interleukins or by affecting thrombus formation [8].Subsets of B cells
Experimental studies suggest an important role for B
cells in atherogenesis. Initial evidence came from sple-
nectomized ApoE–/– mice developing more severe ath-
erosclerosis compared to sham-treated mice, followed by
an impressive attenuation of atherosclerosis after trans-
fer of splenic B cells [9]; however, subsequent studies
showed conflicting results and the current understand-
ing suggests a differential role according to B cell subsets
[10, 11]. The same theory might be postulated for acute
MI. We hypothesized that an increased number of hu-
man B CD11b– cells may decrease infarcted mass afterreperfusion of an occluded coronary artery. In addition,
an increased number of B2 cells, which are considered
proatherogenic, may increase the infarcted mass [12].
Other possible players such as highly inflammatory T
cells, lymphocyte-derived microparticles, extracellular
vesicles, and exosomes may also reach the damaged
myocardium, affecting the clotting process [8], oxidative
stress [13], and microcirculation [14], thus influencing
the recovery of the ischemic tissue [14]. We previously
reported that hyperlipidemic individuals treated with
rosuvastatin presented better immune responses (higher
titers of anti-oxLDL) than those receiving simvastatin/
ezetimibe, thus suggesting that the choice of lipid lower-
ing therapy may have possible beneficial role in the acute
phase of myocardial infarction [15]. Figure 1 summarizes
the study hypothesis regarding B and T lymphocytes.Microcirculation and the role of ticagrelor/rosuvastatin
In addition to its antiplatelet properties via P2Y12 recep-
tor antagonism, ticagrelor (but not clopidogrel) increases
adenosine plasma levels in individuals with acute coron-
ary syndromes [16]. An increase in adenosine concentra-
tion following ticagrelor use seems related to the
inhibition of the adenosine transporter ENT1 (type 1
equilibrative nucleoside transporter) [17]. This effect of
ticagrelor increases coronary blood flow and might be
important in the early protection of the ischemic tissue
in the acute phase of MI [18].
Rosuvastatin is an active substrate for
hydroxymethylglutaryl-Coenzyme A reductase, decreas-
ing the pathway of endogenous cholesterol synthesis.
Fig. 1 The BATTLE-AMI hypothesis – lymphocytes. After successful coronary reperfusion by a pharmacoinvasive strategy, patients with STEMI might
have greater or smaller infarcted mass depending on the balance of B and T lymphocytes. B CD11b– and B memory cells seem to be related to smaller
infarcted mass and better left ventricular ejection fraction (LVEF). Conversely, B CD11b + and B-naive cells are possibly related to greater infarcted mass.
The role of B and T derived microparticles, extracellular vesicles, or exosomes in the ischemic tissue after coronary reperfusion is not yet established.
PCI percutaneous coronary intervention
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ated by the inhibition of isoprenoids, such as farnesyl-
pyrophosphate and geranylgeranyl pyrophosphate,
intermediate substances in the endogenous cholesterol
synthesis, required for post-translational changes of
small proteins. Consequently, there is a decrease in the
intracellular signaling mediated by Rho GTPases. De-
crease in Rho protein is followed by increased bioavail-
ability of nitric oxide, promoting vasodilation [19].
Simvastatin is a prodrug that needs metabolization via
cytochrome P450, isoenzymes 3A4. Only after this step,
the formed metabolites serve as substrates for the hydro-
xymethylglutaryl CoA reductase, allowing the inhibition
of cholesterol synthesis and promoting pleiotropic ef-
fects. However, thyenopyridines are also substrates for
the same microsomal isoenzymes and some degree of
pharmacokinetic interaction can be expected [20, 21].
Thus, another hypothesis of the BATTLE-AMI study is
that by acting synergistically, the use of ticagrelor plus
rosuvastatin could promote greater improvement in the
microcirculation (Fig. 2). Previous studies have shown
that the use of high-dose statin decreases biomarkers of
myocardial damage in patients undergoing cardiac per-
cutaneous coronary intervention, suggesting early im-
provement in microcirculation [22, 23].Methods
Study population and randomization
The BATTLE-AMI study (NCT02428374) will include
approximately 300 men and women aged > 18 years with
documented STEMI submitted to fibrinolytic therapy(tenecteplase, TNK) in the first 6 h of onset of symptoms
in public hospitals of São Paulo, Brazil, as part of the SP
STEMI treatment network (NCT01791764) [24]. In the
network routine, patients are subsequently transferred to
a tertiary teaching hospital and undergo systematic early
invasive coronary angiography (<24 h, designated as
pharmacoinvasive strategy). After obtaining written in-
formed consent in the teaching hospital and before cor-
onary angiography, eligible patients will be randomized
using a central computerized system in the first 24 h to
one of the four open-label treatment assignments (daily
doses) in a 1:1:1:1 ratio: rosuvastatin 20 mg/ticagrelor
180 mg, rosuvastatin 20 mg/clopidogrel 75 mg, simva-
statin 40 mg plus ezetimibe 10 mg/ticagrelor 180 mg, or
simvastatin 40 mg plus ezetimibe 10 mg/clopidogrel
75 mg. Patients with prior MI, a history of revasculariza-
tion or stroke, contraindication to study drugs, chronic
kidney disease, active liver disease, malignancies,
hematological or rheumatic diseases, or showing clinical
instability requiring rescue catheterization will be
excluded. Other anti-platelet agents or lipid-lowering
drugs than those assigned to participants will be
prohibited.
Individuals with adverse harmful side effects related to
study drugs will be discontinued from trial protocol.
Monitoring of adherence to study drugs will be per-
formed by study drug return. Assessment of adherence
to study medication and concomitant treatment, as well
as patient retention, will be performed at each medical
visit and by phone calls. Individuals that discontinue
study medication will be followed in the study center ac-
cording to the scheduled visits of the study.
Fig. 2 The BATTLE-AMI hypothesis – microcirculation. Microcirculation will be improved by adenosine and nitric oxide. Ticagrelor increases intra- and
extracellular levels of adenosine by blocking the adenosine transporter ENT1. Rosuvastatin increases nitric oxide availability through the decrease in the
intracellular signaling mediated by Rho GTPases. Decrease in Rho protein is followed by increased bioavailability of nitric oxide, promoting vasodilation.
Thus, the synergism between rosuvastatin and ticagrelor will improve the microcirculation of the ischemic myocardium decreasing the final infarcted
mass. The absence of effect in adenosine levels following clopidogrel use and the characteristics of simvastatin as a prodrug might have lower beneficial
effect on the microcirculation
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The study design of BATTLE-AMI is shown in Fig. 3.
The primary objective of the study is to compare the ef-
fects of the different antiplatelet/statin therapies in left
ventricular ejection fraction (LVEF) obtained by cardiac
magnetic resonance imaging (cMRI) 30 days post
STEMI. Secondary objectives include the comparison ofFig. 3 The BATTLE-AMI study flowchart. After fibrinolytic therapy performed in
the hospital for coronary angiography and PCI, if necessary. Those patients ad
the four assignments in a 1:1:1:1 ratio (ticagrelor/rosuvastatin, ticagrelor/simva
plus ezetimibe). Blood, urine, and feces samples will be collected at baseline,
flow-cytometry studies. cMRI studies will be performed during peri-hospitalizatreatments on infarcted mass and the percentage of par-
ticipants with LVEF < 40% (by cMRI) at 30 and 180 days
of follow-up. In addition, the relation of subsets of B and
T lymphocytes with the infarcted mass and LVEF will be
examined in samples collected in the first 24 h and at 30
and 180 days post STEMI. Analyses of microbiota, meta-
bolomics, and proteomics will be performed at the samethe 6 h after onset of symptoms, subjects with STEMI will be referred to
mitted to the hospital within 24 h of STEMI will be randomized to one of
statin plus ezetimibe, clopidogrel/rosuvastatin, or clopidogrel/simvastatin
30 days, and 180 days for metabolomics, proteomics, microbiota, and
tion period and at 30 and 180 days
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entiation and metabolites related to cMRI parameters.
Endothelial progenitor cells and microparticles derived
from platelets, endothelium, monocytes, and lympho-
cytes will be quantified at the same time points and their
relationship with cMRI parameters will be evaluated.
Our main hypothesis is that rosuvastatin/ticagrelor
will be superior than simvastatin plus ezetimibe/clopido-
grel, for the cMR parameters. Additionally, the pilot
study indicated that the ezetimibe/clopidogrel was simi-
lar to simvastatin plus ezetimibe/ticagrelor and rosuvas-
tatin/clopidogrel combinations regarding the primary
endpoint and we decided to compare those other groups
(rosuvastatin/clopidogrel and simvastatin plus ezeti-
mibe/ticagrelor) to explore possible mechanisms for the
primary and secondary objectives.
Thereafter, our sample size derivation was done con-
sidering that rosuvastatin/ticagrelor will improve mean
cMRI LVEF by 6% compared to each of the other three
groups, assuming a 13% dropout rate. The alpha level
fixed in 0.05/3 (1.67%) was considered to adjust the glo-
bal alpha error in 5% using Dunnett’s test approach
(many-to-one comparisons).
Study organization
The steering committee of the study is composed of rep-
resentatives from the Universidade Federal de São Paulo
(UNIFESP, São Paulo, Brazil), Instituto Dante Pazzanese
de Cardiologia (IDPC, São Paulo, Brazil), and Research
Institute, Hospital do Coração (HCor, São Paulo, Brazil).
An independent data safety monitoring board was con-
stituted by representatives of the Heart Institute (InCor,
São Paulo, Brazil) and is planned to analyze data three
times during the study to evaluate only safety measures
(serious adverse events, such as bleeding, acute kidney
injury, new myocardial infarction, and mortality). Based
on those parameters, the board may consider removing
an intervention arm or study’s early termination by
safety reasons or LVEF data. Those comparisons will
consider Haybittle-Peto boundary (p < 0.001).
Laboratory analyses
Microparticles and endothelial progenitor cells will be de-
termined by flow-cytometry using specific markers
[25–27]. Subsets of B and T lymphocytes will be evaluated
by flow-cytometry and IgM and interleukins released by
specific B and T cells will be quantified by ELISA for cyto-
kine evaluation and ELISPOT for IgM detection [28].
Metabolomics and proteomics in plasma and urine will be
determined by LC-MS/MS or CE-MS technique [29]. A
methodology for targeted and untargeted metabolomics
will be evaluated by using a pool of bio fluids (urine and
plasma) with some (n = 10) healthy people. All samples
will be submitted to a protein precipitation procedure, toguarantee method repeatability and preserve the chroma-
tographic column. After protein precipitation, the super-
natant will be dried followed by addition of a proper
solvent and analyzed by LC-MS/MS or CE-MS. For untar-
geted metabolomics, in order to evaluate possible sources
of variation during analysis, Quality control samples (QC)
will be processed, which consist of a pool of 5 μL of each
sample (control and treated). Thus, the QCs will be
injected five times in the beginning of the batch, between
every five injections and three at the end of the batch, and
for the targeted metabolomics method, standards and in-
ternal standards will be used.
All data obtained for untargeted metabolomics will be
processed by specific software and all significant metab-
olites will be obtained after statistical analysis by SIMCA
14 software (Umetrics, Umea, Sweden) by multivariate
analysis. All putative metabolites will be analyzed by
using the HMDB and METLIN free databases followed
by KEGG pathway evaluation. Otherwise, the protein
pellet obtained will be dissolved and the proteins
digested according to a well-established procedure [29,
30]. For proteomics, all peptides will be detected by
LC-MS/MS and identified using specific programs to
proteomics field. The proteins differentially expressed in
the four groups, including the three visits, will be
compared.
Microbiota will be analyzed by new-generation sequen-
cing techniques followed by bioinformatics analyses [31].
Cardiac magnetic resonance images
The amount of infarcted mass, LVEF, and microcirculation
will be determined by 3-T cMRI. For left ventricular func-
tion, cMRI images will be acquired using a 3-T scanner.
Patients will be positioned in the supine position with a
phased-array coil placed over the thorax. Repeated breath-
holds and gating to the electrocardiogram will be applied
to minimize the influence of cardiac and respiratory mo-
tion on data collection. Cine cMRI will be performed
using a steady-state free-precession technique (fast im-
aging employing steady-state acquisition). We will obtain
cine images in the two-chamber, four-chamber, left ven-
tricular outflow tract, and short-axis views, the later with
the first slice positioned at the basis covering the mitral
valve and the last slice covering the apex, resulting in
10–12 cine breath-hold short-axis images to cover the en-
tire left ventricle. Ischemia detection will be performed
using first-pass perfusion imaging in the short-axis orien-
tation only, with at least three slices (the maximum num-
ber of slices will be limited by heart rate). Infarction
detection and quantification images will be acquired using
the myocardial delayed enhancement technique, after the
injection of a commercially available gadolinium-based
contrast agent, administered intravenously at a dose of
0.15 mmol per kilogram of body weight. Contrast-
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those used for cine MRI, with the use of a segmented
inversion-recovery sequence. Each patient study will be
reviewed by two independent blinded readers using
dedicated software. LV function will be calculated using
cine images to measure LVEF, volumes, and mass accord-
ing to standard methods. Perfusion defects will be deter-
mined solely by subjective visualization. Perfusion defects
will be defined as focal regions of myocardium that had
diminished and/or delayed contrast enhancement
compared with normal myocardium. For each patient
study, each reader will report the likelihood of myocardial
ischemia on a scale of 1 to 3: 1 = definitely normal;
2 = possibly abnormal; and 3 = definitely abnormal.
Delayed-enhancement images will be used for infarctFig. 4 Schedule of enrolment, interventions, and assessments. TICA ticagre
cMRI cardiac magnetic resonance imagingcharacterization. Myocardial tissue for each patient will be
classified as hyper-enhanced (scar tissue) or normally en-
hanced myocardium after the observer, through manual
interaction, defined a region of interest (ROI) within
remote non-infarcted territory. The endocardial and epi-
cardial borders will also be defined by manual interaction.
Hyper-enhanced tissue is defined as areas with a signal
intensity of > 2 standard deviations from the mean signal
intensity measured in remote areas within the manually
predefined ROI.
Angiographic analysis
Patients will undergo coronary angiography in the first
24 h of STEMI and percutaneous intervention when
needed. An independent angiographic laboratory willlor, RSV rosuvastatin, Sinva simvastatin, CLO clopidogrel, EZE ezetimibe,
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quantitative coronary angiography (Medis Medical
Imaging System, Leiden, The Netherlands), blinded to
randomization assignment and clinical outcomes (Escola
Paulista de Medicina, Unifesp, São Paulo). TIMI flow in
the infarct vessel will be assessed as previously reported
[32], in which blood flow with a grade of < 3 (0–2) indi-
cates suboptimal flow and blood flow with a grade of 3
indicates normal flow within the vessel. Myocardial blush
grade and TIMI frame count will be used to quantify myo-
cardial tissue level perfusion. Quantitative coronary ana-
lysis will include both baseline and post procedure:
proximal, distal and interpolated reference diameter; per-
cent stenosis; minimal lumen diameter; and lesion length.
Qualitative analysis will include: the presence of
thrombus; tortuosity; calcification; plaque rupture; and an-
eurisms. The Syntax score (SS) will be calculated by an
experienced interventional cardiologist blinded to treat-
ment assignment, type of stent used and clinical out-
comes. Each lesion with ≥ 50% diameter stenosis in
vessels ≥ 1.5 mm will be scored using the SS algorithm,
which has been fully described elsewhere [33, 34] and is
available on the SS website (www.syntaxscore.com).
Data collection and analyses
Data collection will be performed centrally. Recommen-
dations for Interventional Trials (SPIRIT) is described in
Fig. 4. A SPIRIT Checklist is included as an Additional
file (Additional file 1).
This is an open label study, with outcome assessors
and data analysts blinded to treatment assignment.
Discussion
The BATTLE-AMI study will address important topics
in the treatment of STEMI after a pharmacoinvasive
strategy. First, the trial will examine whether the use of
rosuvastatin/ticagrelor will be followed by improvement
in the LVEF and smaller infarcted mass. The mecha-
nisms involved will be examined by metabolomics and
proteomics, including the measurement of adenosine.
Second, the trial will evaluate the role of subsets of lym-
phocytes in the final infarcted mass and ventricular re-
modeling, exploring B and T cells phenotypes. For this
analysis, the absolute number of subtypes of lympho-
cytes will be correlated with cMRI parameters as well as
with those parameters obtained in the coronary angio-
gram. We expect that increased number of lymphocytes
of more inflammatory phenotypes will be related to re-
perfusion injury, thus influencing the final infarcted
mass and LVEF at 30 days post MI. Third, the effects of
microbiota on the cMRI parameters and lymphocytes
differentiation will be examined. We expect that the
presence of a pathological microbiota may contribute to
lymphocyte phenotype differentiation. Finally, therelationship among microparticles derived from endo-
thelium, platelets, and leukocytes with the cMRI param-
eters will be addressed. This analysis will test the
relevance of these new vascular biomarkers in the cor-
onary heart disease and possible influences of the treat-
ments. Thus, the trial will review the role of two major
players considered to be involved with ventricular re-
modeling and infarcted mass size: inflammation and
microcirculation under highly effective lipid lowering
therapies.
Trial status
The first patient was included in the trial on May 2015
and patient recruitment is ongoing.
Additional file
Additional file 1: SPIRIT checklist. (DOC 122 kb)
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